Novartis Del Desiran Impairment Exposes the Cost of Acquired Pipeline Risk
Novartis del desiran impairment reveals how a trial miss reduced acquired research value, stranded manufacturing capacity and tested capital allocation.
Read the story
Language
Search languages…
No languages found
104 languages available
No languages found
104 languages available
Novartis del desiran impairment reveals how a trial miss reduced acquired research value, stranded manufacturing capacity and tested capital allocation.
Read the story
Novartis is paying $575 million upfront for Abogen’s mRNA platform while keeping most of a $7.8 billion headline contingent. The real test is disciplined…
Read the story